Nymox Pharmaceutical Corp (NYMX) 5.04 $NYMX
5 Stocks Poised for Breakouts
at The Street - Fri Apr 11, 7:23AM CDT
These stocks look ready to break out and trade higher from current levels.
Nymox Pharmaceutical announces lower net loss of USD4.91m in 2013
M2 - Mon Mar 17, 7:45AM CDT
Therapeutics company Nymox Pharmaceutical (NasdaqCM:NYMX) on Friday declared a net loss of USD4.91m (USD0.14 per share) for the year ended 31 December 2013.
Nymox Reports 2013 Financial Results
GlobeNewswire - Fri Mar 14, 12:00PM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2013 prepared in accordance with International Financial Reporting Standards. Nymox reported a net loss of $4,908,603, or $0.14 per share for the year ended December 31, 2013, compared to $7,627,589, or $0.23 per share for same period in 2012. The decrease of the net loss for the year is attributable primarily to a reduction of stock-based compensation charges which were $307,326 in 2013 compared to $1,962,085 in 2012. The weighted average number of common shares outstanding for the year ended December 31, 2013 was 34,147,666, compared to 33,176,185 for the same period in 2012.
Nymox Pharmaceutical Corporation names Andre Monette as CFO
M2 - Thu Feb 06, 5:25AM CST
Biopharmaceutical company Nymox Pharmaceutical Corporation (NasdaqCM:NYMX) revealed on Wednesday that it has appointed Andre Monette as its chief financial officer.
Nymox Announces Appointment of Andre Monette
GlobeNewswire - Wed Feb 05, 1:00PM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the appointment of Andre Monette as Chief Financial Officer of the Company. Mr. Monette, who is a Chartered Professional Accountant and Chartered Financial Analyst, brings to the company extensive experience and expertise in the financial and securities sectors as an executive in the securities industry and as a CFO of a public company. Mr. Monette served for seventeen years as Vice President of Finance and Administration for the North American subsidiary of Lombard Odier Group, a private Swiss bank based in Geneva. Prior to joining Nymox he provided corporate consulting services in financial reporting.
Nymox Provides Update on NX-1207 Phase 3 BPH and Phase 2 Prostate Cancer Clinical Trial Activities
GlobeNewswire - Tue Jan 28, 10:30AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today provided updates on pivotal Phase 3 development activities for NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), a common affliction of older men. NX-1207 is also in development in Phase 2 for localized prostate cancer. The Company's two large pivotal prospective double blind placebo-controlled U.S. clinical trials (NX02-0017 and NX02-0018) have completed enrollment. One open label safety study (NX02-0020) of subjects who have received a second injection of NX-1207 has completed enrollment and 6 month data has been reported previously. A second open label reinjection study (NX02-0022) is in progress. In Europe, patient recruitment is ongoing at investigational sites in five major European countries in a Phase 3 blinded comparator-controlled clinical trial under the sponsorship of the Company's European licensing partner, Recordati S.p.A.
No Plans to Turn Save Valley Conservancy Into National Park
by Alex Bell - All Africa Global Media - Wed Jan 22, 2:12AM CST
Authorities at the Save valley Conservancy have denied claims that plans are underway to turn the area into a national park, after reports quoted the new tourism minister as saying this was in the pipeline.
Nymox Closes Recruitment for NX-1207 Phase 2 Prostate Cancer Trial
GlobeNewswire - Mon Jan 13, 9:00AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced that recruitment is being closed for the Company's Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) and that enrollment will be formally completed shortly. Initial top line study results are expected to be available approximately 6-8 weeks after completion of enrollment.
Nymox Reports Third Quarter 2013 Financial Results
GlobeNewswire - Thu Nov 14, 9:15AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the third quarter of 2013. Nymox reported a net loss of $1,020,387, or $0.03 per share, for the quarter and $3,591,682, or $0.11 per share, for the nine months ended September 30, 2013, compared to $1,245,563, or $0.04 per share, for the quarter and $4,813,666, or $0.15 per share, for the nine months ended September 30, 2012. The decrease in net losses in 2013 compared to 2012 is related to reductions in many areas of expenditures mainly due to a reduction in clinical trial expenditures as the NX-1207 studies near completion.
Nymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH
GlobeNewswire - Mon Nov 11, 10:45AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported a favorable update and recent Safety Monitoring Committee review of safety data for the Company's NX02-0022 reinjection study for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The most recent Safety Monitoring Committee meeting found no significant safety concerns to date. Enrollment in this study at participating investigational sites across the U.S. has passed the 50% accrual level.
Staphylococcal Infections - Pipeline Review, H2 2013
M2 - Wed Nov 06, 3:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/93vjzk/staphylococcal) has announced the addition of the "Staphylococcal Infections - Pipeline Review, H2 2013" report to their offering. 'Staphylococcal Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Staphylococcal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Staphylococcal Infections. Scope - A snapshot of the global therapeutic scenario for Staphylococcal Infections. - A review of the Staphylococcal Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Staphylococcal Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Staphylococcal Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Staphylococcal Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Affinium Pharmaceuticals, Inc. Nymox Pharmaceutical Corporation Evolva SA Destiny Pharma Ltd. Viral Genetics, Inc. Sequoia Sciences, Inc. TAXIS Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/93...hylococcal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Escherichia Coli Infections - Pipeline Review, H2 2013
M2 - Wed Nov 06, 2:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/cr359v/escherichia_coli) has announced the addition of the "Escherichia Coli Infections - Pipeline Review, H2 2013" report to their offering. 'Escherichia Coli Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Escherichia Coli Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections. Scope - A snapshot of the global therapeutic scenario for Escherichia Coli Infections. - A review of the Escherichia Coli Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Escherichia Coli Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genentech, Inc. Rib-X Pharmaceuticals, Inc. Affinium Pharmaceuticals, Inc. BELLUS Health Inc NovaBay Pharmaceuticals, Inc. Nymox Pharmaceutical Corporation Achaogen Inc. Evolva SA GlycoVaxyn AG Pt. Bio Farma Zymenex A/S Sequoia Sciences, Inc. Cellceutix Corporation TheraCarb Inc. Phico Therapeutics Ltd. AvidBiotics Corp. Trana Discovery, Inc. Cantab Biopharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/cr...ichia_coli About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Daily Alert Stock Watch - Nymox Pharmaceutical Corporation, (NASDAQ: NYMX)
WorldStockWire - Wed Sep 11, 9:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Nasdaq stocks posting largest percentage decreases
AP - Mon Sep 09, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Urinary Tract Infections - Pipeline Review, H2 2013
M2 - Thu Sep 05, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q89r4h/urinary_tract) has announced the addition of the "Urinary Tract Infections - Pipeline Review, H2 2013" report to their offering. 'Urinary Tract Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Urinary Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Tract Infections. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections.Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Involved in Urinary Tract Infections Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Toyama Chemical Co. Ltd - Paratek Pharmaceuticals, Inc. - NovaBay Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - Plethora Solutions Holdings plc - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - ConjuGon, Inc. - Osel Inc. - Pinnacle Pharmaceuticals, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/q8...nary_tract
Shares of NYMX Up 23.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 03, 9:36AM CDT
SmarTrend identified an Uptrend for Nymox Pharmaceutical (NASDAQ:NYMX) on July 16th, 2013 at $6.32. In approximately 2 months, Nymox Pharmaceutical has returned 23.52% as of today's recent price of $7.80.
Shares of NYMX Up 18.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Aug 26, 9:24AM CDT
SmarTrend identified an Uptrend for Nymox Pharmaceutical (NASDAQ:NYMX) on July 16th, 2013 at $6.32. In approximately 1 month, Nymox Pharmaceutical has returned 18.61% as of today's recent price of $7.49.
Nymox Reports Positive Results of Safety Monitoring Committee Review of NX02-0018 Phase 3 Trial
GlobeNewswire - Thu Aug 22, 9:15AM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported favorable results from the most recent Safety Monitoring Committee periodic review of safety data for the Company's NX02-0018 clinical trial, one of the two Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The August 20, 2013 Safety Monitoring Committee meeting found no significant safety concerns to date. Both of the Company's pivotal Phase 3 trials have completed enrollment and treatment (a single intraprostatic injection of either drug or placebo) and patient evaluation is continuing at over 70 well-known urology investigative sites across the U.S.
5 Stocks Poised for Breakouts
at The Street - Fri Apr 11, 7:23AM CDT
These stocks look ready to break out and trade higher from current levels.
Nymox Pharmaceutical announces lower net loss of USD4.91m in 2013
M2 - Mon Mar 17, 7:45AM CDT
Therapeutics company Nymox Pharmaceutical (NasdaqCM:NYMX) on Friday declared a net loss of USD4.91m (USD0.14 per share) for the year ended 31 December 2013.
Nymox Reports 2013 Financial Results
GlobeNewswire - Fri Mar 14, 12:00PM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2013 prepared in accordance with International Financial Reporting Standards. Nymox reported a net loss of $4,908,603, or $0.14 per share for the year ended December 31, 2013, compared to $7,627,589, or $0.23 per share for same period in 2012. The decrease of the net loss for the year is attributable primarily to a reduction of stock-based compensation charges which were $307,326 in 2013 compared to $1,962,085 in 2012. The weighted average number of common shares outstanding for the year ended December 31, 2013 was 34,147,666, compared to 33,176,185 for the same period in 2012.
Nymox Pharmaceutical Corporation names Andre Monette as CFO
M2 - Thu Feb 06, 5:25AM CST
Biopharmaceutical company Nymox Pharmaceutical Corporation (NasdaqCM:NYMX) revealed on Wednesday that it has appointed Andre Monette as its chief financial officer.
Nymox Announces Appointment of Andre Monette
GlobeNewswire - Wed Feb 05, 1:00PM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the appointment of Andre Monette as Chief Financial Officer of the Company. Mr. Monette, who is a Chartered Professional Accountant and Chartered Financial Analyst, brings to the company extensive experience and expertise in the financial and securities sectors as an executive in the securities industry and as a CFO of a public company. Mr. Monette served for seventeen years as Vice President of Finance and Administration for the North American subsidiary of Lombard Odier Group, a private Swiss bank based in Geneva. Prior to joining Nymox he provided corporate consulting services in financial reporting.
Nymox Provides Update on NX-1207 Phase 3 BPH and Phase 2 Prostate Cancer Clinical Trial Activities
GlobeNewswire - Tue Jan 28, 10:30AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today provided updates on pivotal Phase 3 development activities for NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), a common affliction of older men. NX-1207 is also in development in Phase 2 for localized prostate cancer. The Company's two large pivotal prospective double blind placebo-controlled U.S. clinical trials (NX02-0017 and NX02-0018) have completed enrollment. One open label safety study (NX02-0020) of subjects who have received a second injection of NX-1207 has completed enrollment and 6 month data has been reported previously. A second open label reinjection study (NX02-0022) is in progress. In Europe, patient recruitment is ongoing at investigational sites in five major European countries in a Phase 3 blinded comparator-controlled clinical trial under the sponsorship of the Company's European licensing partner, Recordati S.p.A.
No Plans to Turn Save Valley Conservancy Into National Park
by Alex Bell - All Africa Global Media - Wed Jan 22, 2:12AM CST
Authorities at the Save valley Conservancy have denied claims that plans are underway to turn the area into a national park, after reports quoted the new tourism minister as saying this was in the pipeline.
Nymox Closes Recruitment for NX-1207 Phase 2 Prostate Cancer Trial
GlobeNewswire - Mon Jan 13, 9:00AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced that recruitment is being closed for the Company's Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) and that enrollment will be formally completed shortly. Initial top line study results are expected to be available approximately 6-8 weeks after completion of enrollment.
Nymox Reports Third Quarter 2013 Financial Results
GlobeNewswire - Thu Nov 14, 9:15AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the third quarter of 2013. Nymox reported a net loss of $1,020,387, or $0.03 per share, for the quarter and $3,591,682, or $0.11 per share, for the nine months ended September 30, 2013, compared to $1,245,563, or $0.04 per share, for the quarter and $4,813,666, or $0.15 per share, for the nine months ended September 30, 2012. The decrease in net losses in 2013 compared to 2012 is related to reductions in many areas of expenditures mainly due to a reduction in clinical trial expenditures as the NX-1207 studies near completion.
Nymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH
GlobeNewswire - Mon Nov 11, 10:45AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported a favorable update and recent Safety Monitoring Committee review of safety data for the Company's NX02-0022 reinjection study for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The most recent Safety Monitoring Committee meeting found no significant safety concerns to date. Enrollment in this study at participating investigational sites across the U.S. has passed the 50% accrual level.
Staphylococcal Infections - Pipeline Review, H2 2013
M2 - Wed Nov 06, 3:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/93vjzk/staphylococcal) has announced the addition of the "Staphylococcal Infections - Pipeline Review, H2 2013" report to their offering. 'Staphylococcal Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Staphylococcal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Staphylococcal Infections. Scope - A snapshot of the global therapeutic scenario for Staphylococcal Infections. - A review of the Staphylococcal Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Staphylococcal Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Staphylococcal Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Staphylococcal Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Affinium Pharmaceuticals, Inc. Nymox Pharmaceutical Corporation Evolva SA Destiny Pharma Ltd. Viral Genetics, Inc. Sequoia Sciences, Inc. TAXIS Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/93...hylococcal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Escherichia Coli Infections - Pipeline Review, H2 2013
M2 - Wed Nov 06, 2:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/cr359v/escherichia_coli) has announced the addition of the "Escherichia Coli Infections - Pipeline Review, H2 2013" report to their offering. 'Escherichia Coli Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Escherichia Coli Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections. Scope - A snapshot of the global therapeutic scenario for Escherichia Coli Infections. - A review of the Escherichia Coli Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Escherichia Coli Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genentech, Inc. Rib-X Pharmaceuticals, Inc. Affinium Pharmaceuticals, Inc. BELLUS Health Inc NovaBay Pharmaceuticals, Inc. Nymox Pharmaceutical Corporation Achaogen Inc. Evolva SA GlycoVaxyn AG Pt. Bio Farma Zymenex A/S Sequoia Sciences, Inc. Cellceutix Corporation TheraCarb Inc. Phico Therapeutics Ltd. AvidBiotics Corp. Trana Discovery, Inc. Cantab Biopharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/cr...ichia_coli About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Daily Alert Stock Watch - Nymox Pharmaceutical Corporation, (NASDAQ: NYMX)
WorldStockWire - Wed Sep 11, 9:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Nasdaq stocks posting largest percentage decreases
AP - Mon Sep 09, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Urinary Tract Infections - Pipeline Review, H2 2013
M2 - Thu Sep 05, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q89r4h/urinary_tract) has announced the addition of the "Urinary Tract Infections - Pipeline Review, H2 2013" report to their offering. 'Urinary Tract Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Urinary Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Tract Infections. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections.Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Involved in Urinary Tract Infections Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Toyama Chemical Co. Ltd - Paratek Pharmaceuticals, Inc. - NovaBay Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - Plethora Solutions Holdings plc - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - ConjuGon, Inc. - Osel Inc. - Pinnacle Pharmaceuticals, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/q8...nary_tract
Shares of NYMX Up 23.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 03, 9:36AM CDT
SmarTrend identified an Uptrend for Nymox Pharmaceutical (NASDAQ:NYMX) on July 16th, 2013 at $6.32. In approximately 2 months, Nymox Pharmaceutical has returned 23.52% as of today's recent price of $7.80.
Shares of NYMX Up 18.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Aug 26, 9:24AM CDT
SmarTrend identified an Uptrend for Nymox Pharmaceutical (NASDAQ:NYMX) on July 16th, 2013 at $6.32. In approximately 1 month, Nymox Pharmaceutical has returned 18.61% as of today's recent price of $7.49.
Nymox Reports Positive Results of Safety Monitoring Committee Review of NX02-0018 Phase 3 Trial
GlobeNewswire - Thu Aug 22, 9:15AM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported favorable results from the most recent Safety Monitoring Committee periodic review of safety data for the Company's NX02-0018 clinical trial, one of the two Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The August 20, 2013 Safety Monitoring Committee meeting found no significant safety concerns to date. Both of the Company's pivotal Phase 3 trials have completed enrollment and treatment (a single intraprostatic injection of either drug or placebo) and patient evaluation is continuing at over 70 well-known urology investigative sites across the U.S.
